Progyny (NASDAQ:PGNY) Price Target Raised to $25.00

Progyny (NASDAQ:PGNY) had its price target lifted by Bank of America from $21.00 to $25.00 in a report published on Tuesday,Benzinga reports. Bank of America currently has a buy rating on the stock.

PGNY has been the subject of a number of other reports. Barclays cut their price objective on Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Canaccord Genuity Group cut their price objective on Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research report on Wednesday, November 13th. JPMorgan Chase & Co. lifted their price target on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $19.00 price target (down from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $25.83.

Progyny Trading Down 0.3 %

Shares of PGNY stock opened at $21.95 on Tuesday. The stock has a 50 day moving average of $18.90 and a 200 day moving average of $18.85. The stock has a market cap of $1.87 billion, a P/E ratio of 37.85, a P/E/G ratio of 2.18 and a beta of 1.34. Progyny has a twelve month low of $13.39 and a twelve month high of $42.08.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). The business had revenue of $286.63 million during the quarter, compared to analysts’ expectations of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.16 earnings per share. On average, research analysts predict that Progyny will post 0.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Progyny

In other news, CEO Peter Anevski acquired 209,500 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the acquisition, the chief executive officer now owns 441,463 shares of the company’s stock, valued at $6,392,384.24. This represents a 90.32 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman David J. Schlanger acquired 150,000 shares of the business’s stock in a transaction that occurred on Thursday, December 26th. The stock was purchased at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the acquisition, the chairman now directly owns 228,269 shares in the company, valued at approximately $3,350,988.92. This trade represents a 191.65 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Progyny

Several large investors have recently bought and sold shares of PGNY. Pacer Advisors Inc. increased its holdings in Progyny by 12,579.4% during the 3rd quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company’s stock worth $41,777,000 after purchasing an additional 2,472,983 shares during the period. International Assets Investment Management LLC boosted its position in shares of Progyny by 1,576.0% during the 3rd quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company’s stock worth $42,991,000 after acquiring an additional 2,412,068 shares in the last quarter. Invenomic Capital Management LP acquired a new position in shares of Progyny during the 3rd quarter worth about $29,509,000. River Road Asset Management LLC acquired a new position in shares of Progyny during the 4th quarter worth about $25,529,000. Finally, Fort Washington Investment Advisors Inc. OH boosted its position in shares of Progyny by 90.1% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock worth $25,319,000 after acquiring an additional 695,740 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.